Free Trial
NASDAQ:CDTX

Cidara Therapeutics (CDTX) Stock Price, News & Analysis

Cidara Therapeutics logo
$22.18 +0.48 (+2.21%)
As of 01/21/2025 04:00 PM Eastern

About Cidara Therapeutics Stock (NASDAQ:CDTX)

Key Stats

Today's Range
$21.64
$22.68
50-Day Range
$13.90
$27.30
52-Week Range
$10.00
$28.42
Volume
82,659 shs
Average Volume
142,855 shs
Market Capitalization
$156.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.20
Consensus Rating
Buy

Company Overview

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cidara Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
81st Percentile Overall Score

CDTX MarketRank™: 

Cidara Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 240th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cidara Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Cidara Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cidara Therapeutics are expected to decrease in the coming year, from ($8.74) to ($14.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cidara Therapeutics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cidara Therapeutics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    1.65% of the float of Cidara Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cidara Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cidara Therapeutics has recently increased by 113.57%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cidara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cidara Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.65% of the float of Cidara Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cidara Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cidara Therapeutics has recently increased by 113.57%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cidara Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Cidara Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for CDTX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cidara Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.64% of the stock of Cidara Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 35.82% of the stock of Cidara Therapeutics is held by institutions.

  • Read more about Cidara Therapeutics' insider trading history.
Receive CDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CDTX Stock News Headlines

Cidara Therapeutics Inc CDTX
Stunning Trump Manhattan Project Now Underway
Just as I predicted, President Trump announced his #1 move during his first 100 days... His allies are calling it Trump’s Manhattan Project.
Twelve option delistings on December 23rd
See More Headlines

CDTX Stock Analysis - Frequently Asked Questions

Cidara Therapeutics' stock was trading at $26.88 on January 1st, 2025. Since then, CDTX stock has decreased by 17.5% and is now trading at $22.18.
View the best growth stocks for 2025 here
.

Cidara Therapeutics, Inc. (NASDAQ:CDTX) announced its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($7.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($7.20) by $0.20. The biotechnology company earned $7.08 million during the quarter, compared to the consensus estimate of $3.62 million. Cidara Therapeutics had a negative trailing twelve-month return on equity of 69.64% and a negative net margin of 289.05%.

Cidara Therapeutics's stock reverse split before market open on Wednesday, April 24th 2024. The 1-20 reverse split was announced on Wednesday, April 24th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Cidara Therapeutics (CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cidara Therapeutics investors own include Meta Platforms (META), VBI Vaccines (VBIV), SCYNEXIS (SCYX), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Sorrento Therapeutics (SRNE) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/10/2021
Today
1/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CDTX
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.20
High Stock Price Target
$45.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+45.2%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Net Income
$-22,930,000.00
Net Margins
-289.05%
Pretax Margin
-514.62%

Debt

Sales & Book Value

Annual Sales
$44.65 million
Book Value
($1.82) per share

Miscellaneous

Free Float
6,509,000
Market Cap
$156.30 million
Optionable
No Data
Beta
0.98

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:CDTX) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners